What Climen Ciclica Treats: Main Uses and Benefits

---

The primary purpose of Climen Ciclica is to provide hormonal substitution, addressing symptoms and long-term health concerns arising from estrogen deficiency during the climacteric and postmenopausal periods. Its therapeutic use is concentrated in critical domains of patient need.

This medication is generally used to help with the intensity and frequency of severe vasomotor symptoms (such as hot flashes and night sweats), urogenital atrophy (like vaginal dryness), and associated sleep disturbances that create noticeable physiological strain. It is also relevant for managing states of severe estrogen deficiency following procedures like ovariectomy or for conditions like gonadal failure (hypogonadism). The therapy may be part of symptomatic management for long-term health concerns by assisting with functional stability related to bone density and reducing the risk of fractures in postmenopausal women who are at increased risk.

“The sequential structure is commonly used to help with management related to the cyclical hormonal requirement for all women with an intact uterus.”

The symptomatic support contributes to easing the overall symptom load, assists with maintaining functional stability, and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact
Relief for	Systemic Symptoms and Urogenital Discomfort

Who can and cannot use Climen Ciclica?

Eligibility to use Climen Ciclica (Estradiol Valerate and Cyproterone Acetate) is strictly defined by regulatory documents, focusing on patient status, medical history, and specific conditions. The medicine is primarily indicated for postmenopausal women who retain an intact uterus, which is a mandatory condition for this sequential therapy.

---

Absolute Contraindications (Must Not Use)

Population/Condition
Current or previous breast cancer or other oestrogen-dependent malignant tumours.
Current or previous venous or arterial thromboembolic disorders (e.g., DVT, stroke, MI).
Severe hepatic disease or a history of liver tumours or meningioma.
Undiagnosed genital bleeding, untreated endometrial hyperplasia, or porphyria.
Pregnancy and lactation (breast-feeding).

---

Population Restrictions

Age Group/Status	Regulatory Status
Paediatric Population	Not indicated for use in children and adolescents.
Renal Impairment	Not specifically studied; no established data for dose adjustment.

Close medical monitoring is also required for conditions like hypertension, diabetes mellitus, and certain pre-existing uterine conditions like leiomyoma.

The official regulatory documentation for Climen Ciclica outlines several documented interaction patterns that affect the active hormonal components, Estradiol Valerate and Cyproterone Acetate.

Pharmacokinetic Interactions

• Reduced Exposure: Co-administration with liver enzyme-inducing substances accelerates the metabolism of the steroid hormones. Specific medicines cited include Rifampicin, Barbiturates, Hydantoins, and Phenylbutazone, which may reduce plasma concentrations and lead to a possible impairment of therapeutic effect.
• GI Flora Effects: Certain antibiotics (e.g., Ampicillin) are officially noted to cause reduced substance levels due to alteration of the intestinal flora.
• Increased Exposure: Inhibitors of the primary metabolic pathway, such as strong CYP3A4 inhibitors, may increase the plasma concentrations of the steroid hormones.

Pharmacodynamic and Other Interactions

• Glucose Metabolism: A pharmacodynamic effect on glucose tolerance is documented, which necessitates monitoring for a change in the patient's requirement for co-administered antidiabetics or insulin.
• Herbal Products: St. John's Wort preparations are cited as having the potential to reduce hormone levels due to enzyme induction.
• Food Products: Grapefruit juice is documented as a substance that may increase hormonal component levels via enzyme inhibition.
• Population Note: Close monitoring is required for patients with impaired liver function due to the potential for slower clearance of the hormonal components and subsequent increased effect.

Hormone Receptor Agonism and Systemic Influence

The medication's mechanism centers on activating estrogen receptors (ERs) and progestin receptors (PRs) across various tissues. The estradiol component acts as an agonist on ERs, initiating signaling cascades that influence bone remodeling processes and the activity of central thermoregulatory centers in the brain. This receptor activation influences systemic physiological systems.

---

Sequential Endometrial Regulation

The sequential delivery of hormones is specifically designed to modulate the tissue lining of the uterus (endometrium). The estrogen phase promotes cell growth (proliferation), which the subsequent progestin component counters by inducing a secretory transformation. The programmed withdrawal of the progestin then triggers the predictable, controlled shedding of the lining, a mechanism that leads to the tissue's cyclic change and shedding.

---

Endocrine Feedback and HPO Axis Influence

The active ingredients engage in negative feedback with the Hypothalamus-Pituitary-Ovarian (HPO) axis, the body's primary endocrine control center. By modulating the release of pituitary hormones, this mechanism influences central endocrine feedback and produces physiological adjustments across hormone-sensitive systems.

Official Administration Guidelines

This section details the procedural structure for using Climen Ciclica.

---

Administration Scope

Property	Instruction
Route of administration	The medication is administered orally.
Dosing schedule	The regimen follows a sequential, cyclical pattern consisting of 21 active tablets followed by a 7-day tablet-free interval. The initial 11 days require the white tablet (Estradiol Valerate 2 mg), and the subsequent 10 days require the pink-coloured tablet (Estradiol Valerate 2 mg / Cyproterone Acetate 1 mg).
Timing in relation to meals	The tablets must be swallowed unchewed with sufficient liquid.
Preparation requirements	None; the tablets are taken directly in their solid form.
Age-group administration rules	The medicine is not indicated for use in children or adolescents. No dose adjustment is indicated for elderly patients.
Missed-dose rules	A forgotten tablet should be taken as quickly as possible. If more than 24 hours have passed since the usual time, the missed tablet is not to be taken, and the cycle continues as scheduled.
Special procedural conditions	The tablets should be taken once daily at the same time of day consistently. Postmenopausal women with amenorrhoea may initiate therapy on any day.

---

Resulting Procedural Structure

Official Step Sequence:

• Begin treatment on the designated starting day (any day for postmenopausal women).
• Take one white tablet daily for the first 11 consecutive days, unchewed with liquid.
• Take one pink-coloured tablet daily for the subsequent 10 consecutive days.
• Observe a tablet-free interval lasting seven days, after which the next 28-day pack is started.

Connection to the Overall Use Protocol

This entire protocol is structured as a continuous 28-day cycle that is repeated without interruption to maintain the standardized dosing pattern. The regimen's core principle is the defined two-phase hormonal delivery schedule, which specifies the exact tablet type and duration for the 21 days of active administration followed by the defined withdrawal interval.

Climen Ciclica: Recent Clinical Evidence

This section summarizes research findings related to the combination of estradiol valerate and cyproterone acetate (Climen Ciclica) used in menopausal hormone therapy.

---

Efficacy in Climacteric Symptoms

Clinical studies have investigated the preparation's influence on common menopausal symptoms across various health and quality-of-life scales. Research has evaluated the effects on the following:

• Vasomotor symptoms: Studies have assessed changes in the frequency and severity of hot flashes in postmenopausal women.
• Psychological and Somatic Symptoms: The combination has been studied for its effects on symptoms such as nervousness, anxiety, depressive moods, and physical complaints, often measured using validated instruments like the Menopause Rating Scale (MRS).
• Androgenization: Research has explored the product's use in women experiencing signs of androgenization (e.g., hair loss) during the peri- and postmenopausal periods.

---

Endometrial Safety

In women with an intact uterus, the use of estrogen-only therapy carries an increased risk of endometrial hyperplasia and cancer. The inclusion of the progestogen, cyproterone acetate, in the sequential regimen is intended to counteract the proliferative effects of the estrogen component, allowing the endometrium to shed and maintaining endometrial safety.

---

Post-Marketing Surveillance and Long-Term Data

Large post-marketing surveillance studies have been conducted to evaluate the product's overall activity and tolerability profile in a wide range of women with menopausal complaints. These studies monitor the long-term impact on various subscores of menopausal severity, confirming that the treatment profile remains consistent over time.

Common questions about Climen Ciclica (FAQ)

---

Q: What is the main difference between Climen Ciclica and other hormone treatments (HRT)?

Climen Ciclica is a type of sequential combined HRT, meaning the hormones are taken in a specific, cyclical pattern. The progestogen component is included for only part of the cycle to modulate the uterine lining, which typically results in a monthly withdrawal bleed.

This differs from continuous combined HRT, where both estrogen and progestogen are taken every day to prevent bleeding.

---

Q: Can Climen Ciclica be used by women who have had a hysterectomy?

No, this combined sequential product is not generally recommended for women who have had a hysterectomy (removal of the uterus).

The progestogen component is included primarily for endometrial protection (safety of the uterine lining). For women without a uterus, regulatory information indicates that oestrogen-only HRT is generally used because the progestogen component is not needed.

---

Q: Is there a maximum length of time Climen Ciclica can be used, based on official guidelines?

Regulatory guidance advises using the lowest effective dose for the shortest possible duration necessary to relieve symptoms.

The risk of certain serious side effects, such as breast cancer and blood clots, is noted to increase with the duration of use. Regulatory documentation states that treatment is intended to be for the shortest possible duration.

---

Q: Is it necessary to have a period while taking Climen Ciclica?

A monthly bleed is the usual expected outcome of taking this sequential combined regimen.

This bleed is medically referred to as a withdrawal bleed and occurs during the tablet-free interval when the progestogen component is withdrawn, allowing the uterine lining to shed as intended.

---

Q: Does using Climen Ciclica mean I am protected from pregnancy?

No. Official product information states that Climen Ciclica is not a contraceptive.

If contraception is needed, regulatory information recommends the use of non-hormonal methods. Furthermore, pregnancy is listed as a contraindication for taking this medicine.

---

Q: What do official documents say about stopping Climen Ciclica suddenly?

Regulatory documents state that therapy must be discontinued immediately if certain critical conditions develop, such as jaundice (yellowing of the skin/eyes), a significant increase in blood pressure, or symptoms indicative of a blood clot.

Specific instruction for general, abrupt cessation for non-critical reasons is not typically provided in official documents. Information is focused only on conditions requiring immediate discontinuation.

---

Q: Can Climen Ciclica affect the results of certain medical tests?

Yes, hormone replacement therapy may affect the results of certain laboratory tests.

Regulatory documents indicate potential effects on various parameters, including blood coagulation (clotting) measures, glucose tolerance, and levels of certain binding proteins in the body.

---

Q: Is there any research evidence on the effects of Climen Ciclica in women who enter menopause early?

While the product is primarily indicated for postmenopausal symptoms, the core regulatory guidance for HRT notes that if a product’s indication includes perimenopausal women (who may be experiencing symptoms of early menopause), official regulatory guidance suggests that evidence on the effects of the combination in this population is part of the clinical evaluation.

How to Store and Dispose of Climen Ciclica

The storage of Climen Ciclica coated tablets must adhere strictly to official regulatory guidelines to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, specifically below 30°C (86°F).
Packaging	Keep the medicine in its original packs and containers.
Protection	Keep out of the reach of children.

️ Disposal Instructions

If the product is expired or unused, it should be disposed of in accordance with local regulations.

• Utilize an authorized drug take-back program or mail-back envelope if available.
• If take-back is unavailable, the medicine must be removed from the original container, mixed with an undesirable substance (such as dirt or used coffee grounds), and placed in a sealed bag before being disposed of in the household trash.
• Do not flush the tablets down the toilet or pour them into any wastewater system.